Distinguishing between adverse and non-adverse effects

Experimental and Toxicologic Pathology

Volumn 54, Issue 1, 2002, Pages 51-55

  Karbe, E ^a   Williams, G M ^b   Lewis, R W ^c   Kimber, I ^c   Foster, P M D ^d  

^a Dept Pathology ^*  (Germany)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Speaker Syngenta Central Toxicology Laboratory   (United Kingdom)

^d CIIT CENTERS FOR HEALTH RESEARCH   (United States)

Author keywords

Adverse effect; Endocrine system; Enzyme induction; Immune system; Liver; NOAEL; NOEL; Non adverse effect

Indexed keywords

4 HYDROXYNONENAL; ANDROGEN; ANTHRACYCLINE; CIPROFIBRATE; ERYTHROMYCIN; ESTROGEN; FIBRIC ACID DERIVATIVE; PHENOBARBITAL; RIFABUTIN; XENOBIOTIC AGENT;

CONFERENCE PAPER; ENDOCRINE SYSTEM; ENZYME INDUCTION; IMMUNE SYSTEM; LIVER; TOXICITY TESTING; ADAPTATION; ANIMAL; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; ENDOCRINE GLAND; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; ORGANIZATION; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; TOXICOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CONGRESSES; ENDOCRINE GLANDS; HUMANS; IMMUNE SYSTEM; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PATHOLOGY; RISK ASSESSMENT; SOCIETIES, SCIENTIFIC; TOXICOLOGY; XENOBIOTICS;

EID: 0036326118     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00233     Document Type: Conference Paper

References (0)